Hans Jørgen Nielsen

TL;DR: In patients with resectable colorectal cancers, higher amounts of preoperative circulating tumor DNA were associated with disease recurrence and decreased overall survival, and a method developed by Phallen et al., called targeted error correction sequencing, demonstrates the feasibility of detecting circulating cell-free DNA from many early tumors, suggesting its potential use for cancer screening.

TL;DR: The first metagenomic profiling study of CRC faecal microbiomes is presented to discover and validate microbial biomarkers in ethnically different cohorts, and to independently validate selected biomarkers using an affordable clinically relevant technology.

TL;DR: Recommendations to encourage optimal use of tumor markers for 5 cancer sites were critically reviewed and alpha-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring.

TL;DR: An approach to evaluate fragmentation patterns of cell-free DNA across the genome was developed, and found that profiles of healthy individuals reflected nucleosomal patterns of white blood cells, whereas patients with cancer had altered fragmentation profiles.

TL;DR: Assessment of ctDNA is a non-invasive, exquisitely specific and highly sensitive approach for monitoring disease load, which has the potential to provide clinically relevant lead times compared with conventional methods.